E

Epizyme Inc
F:EPE

Watchlist Manager
Epizyme Inc
F:EPE
Watchlist
Price: 559 EUR 3.33%
Market Cap: 92.2B EUR
Section:
Relative Value
Relative Value
Valuation Multiples
Multiples Across Competitors
See Also

Relative Value

There is not enough data to reliably calculate the relative value of EPE.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

EPE Relative Value
Base Case
Not Available
E
Worst Case
Base Case
Best Case

Valuation Multiples

1 993.4
P/S
P/S
Price to Sales
1 993.4
vs History
vs Industry
Median 3Y
1 913.5
Median 5Y
1 759.2
Industry
6.9
Forward
1 398.2
More Details
Negative
P/E
P/E
Price to Earnings
N/A
vs History
vs Industry
Median 3Y
-488.3
Median 5Y
-448.9
Industry
22.4
Forward
-348.7
More Details
Negative
P/OCF
P/OCF
Price to OCF
N/A
vs History
vs Industry
Median 3Y
-486.2
Median 5Y
-447
Industry
19.1
More Details
Negative
P/FCFE
P/FCFE
Price to FCFE
N/A
vs History
vs Industry
Median 3Y
-439.8
Median 5Y
-404.3
Industry
23.2
More Details
Negative
P/B
P/B
Price to Book Value
N/A
vs History
vs Industry
Median 3Y
-5 001.2
Median 5Y
-4 598
Industry
2.5
More Details
1 995.1
EV/S
EV/S
Enterprise Value to Sales
1 995.1
vs History
vs Industry
Median 3Y
1 915.1
Median 5Y
1 760.9
Industry
7.5
Forward
1 399.4
More Details
2 640.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
2 640.5
vs History
vs Industry
Median 3Y
2 534.8
Median 5Y
2 330.6
Industry
8.9
More Details
Negative
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
N/A
vs History
vs Industry
Median 3Y
-531.7
Median 5Y
-488.9
Industry
4
More Details
Negative
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
N/A
vs History
vs Industry
Median 3Y
-517.5
Median 5Y
-475.8
Industry
3.7
More Details
Negative
EV/OCF
EV/OCF
Enterprise Value to OCF
N/A
vs History
vs Industry
Median 3Y
-486.7
Median 5Y
-447.5
Industry
4.5
More Details
Negative
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
N/A
vs History
vs Industry
Median 3Y
-486
Median 5Y
-446.9
Industry
3.4
More Details
921.6
EV/IC
EV/IC
Enterprise Value to IC
921.6
vs History
vs Industry
Median 3Y
884.7
Median 5Y
813.5
Industry
4.6
More Details

Multiples Across Competitors

EPE Competitors Multiples
Epizyme Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Epizyme Inc
F:EPE
94.1B EUR 1 993.4 -508.7 -553.9 -539.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 35 341 491.5 -167 972.9 -203 972.6 -201 645
US
Abbvie Inc
NYSE:ABBV
327.6B USD 5.8 77.3 15.4 23.2
US
Amgen Inc
NASDAQ:AMGN
146.1B USD 4.4 35.7 14.8 26.3
US
Gilead Sciences Inc
NASDAQ:GILD
122.3B USD 4.3 254.8 10.1 12.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
110.4B USD 10 -206.1 22.3 23.4
AU
CSL Ltd
ASX:CSL
115.2B AUD 4.8 26.8 16.6 20.8
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60B USD 4.2 13.6 8.1 9.1
US
Seagen Inc
F:SGT
39.3B EUR 19.2 -58.9 -63.4 -57.2
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
33.7B USD 14.3 -124.8 -554.5 -277.9
NL
argenx SE
XBRU:ARGX
30.5B EUR 15.6 41.1 -2 323.3 -1 557.7
P/S Multiple
Revenue Growth P/S to Growth
US
E
Epizyme Inc
F:EPE
Average P/S: 3 213 051.6
1 993.4
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
35 341 491.5
N/A N/A
US
Abbvie Inc
NYSE:ABBV
5.8
7%
0.8
US
Amgen Inc
NASDAQ:AMGN
4.4
4%
1.1
US
Gilead Sciences Inc
NASDAQ:GILD
4.3
3%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
10
10%
1
AU
CSL Ltd
ASX:CSL
4.8
7%
0.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
4.2
6%
0.7
US
S
Seagen Inc
F:SGT
19.2
30%
0.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
14.3
29%
0.5
NL
argenx SE
XBRU:ARGX
15.6
39%
0.4
P/E Multiple
Earnings Growth PEG
US
E
Epizyme Inc
F:EPE
Average P/E: 74.9
Negative Multiple: -508.7 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -167 972.9 N/A N/A
US
Abbvie Inc
NYSE:ABBV
77.3
87%
0.9
US
Amgen Inc
NASDAQ:AMGN
35.7
44%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
254.8
187%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -206.1 N/A N/A
AU
CSL Ltd
ASX:CSL
26.8
16%
1.7
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
13.6
10%
1.4
US
S
Seagen Inc
F:SGT
Negative Multiple: -58.9 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -124.8 N/A N/A
NL
argenx SE
XBRU:ARGX
41.1
28%
1.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
US
E
Epizyme Inc
F:EPE
Average EV/EBITDA: 14.6
Negative Multiple: -553.9 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -203 972.6 N/A N/A
US
Abbvie Inc
NYSE:ABBV
15.4
14%
1.1
US
Amgen Inc
NASDAQ:AMGN
14.8
17%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
10.1
7%
1.4
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.3
18%
1.2
AU
CSL Ltd
ASX:CSL
16.6
11%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
8.1
14%
0.6
US
S
Seagen Inc
F:SGT
Negative Multiple: -63.4 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -554.5 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -2 323.3 N/A N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
US
E
Epizyme Inc
F:EPE
Average EV/EBIT: 19.2
Negative Multiple: -539.1 		N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -201 645 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.2
29%
0.8
US
Amgen Inc
NASDAQ:AMGN
26.3
31%
0.8
US
Gilead Sciences Inc
NASDAQ:GILD
12.7
11%
1.2
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
17%
1.4
AU
CSL Ltd
ASX:CSL
20.8
14%
1.5
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
9.1
13%
0.7
US
S
Seagen Inc
F:SGT
Negative Multiple: -57.2 N/A N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -277.9 N/A N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -1 557.7 N/A N/A

See Also

Summary
EPE intrinsic value, competitors valuation, and company profile.
DCF Valuation
EPE stock valuation using Discount Cash Flow valuation method.
Relative Valuation
EPE stock valuation using valuation multiples.
Wall Street Estimates
EPE price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
EPE stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 253,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.